SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate
- Written by PR Newswire
![]() |
- Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months
- Company expands its global portfolio beyond vaccines into antibody-based preventive technologies
- Growing global R&D network strengthens capabilities in next-generation infectious disease prevention
INCHEON, South Korea, Aug. 14,...















